CLEVELAND, OH, AND WILMINGTON, MA – APRIL 14, 2016
BioMotiv and Charles River Laboratories have formed a strategic partnership in preclinical development. Charles River will be the preferred partner for BioMotiv’s drug development programs, allowing BioMotiv to leverage the scientific and operational advantages of Charles River’s extensive portfolio of capabilities. The partnership includes a $10 million Charles River investment in BioMotiv.

Click here to read more